Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1987 May 1;136(9):929–933.

Beta-blocker therapy and the risk of anaphylaxis.

J H Toogood
PMCID: PMC1491970  PMID: 2882832

Abstract

Beta-blocker therapy is associated with an increase in the severity and, possibly, the incidence of acute anaphylaxis. The population at risk consists of people with allergic conditions who are given a beta-blocker for an unrelated condition. Anaphylaxis under these conditions may be severe, protracted and resistant to conventional treatment because of the beta-adrenergic blockade. Severe or fatal attacks have been triggered by insect stings, the ingestion of allergenic foods or drugs, and injections of radiocontrast media, antisera or immunotherapy antigens. These occurrences are probably infrequent, but their incidence is unknown. At least two fatal cases have recently occurred in Canada. Clinical allergists, internists and family practitioners in particular should be aware of the need for aggressive and prolonged support in patients who experience anaphylaxis while receiving beta-blocker therapy and should report all such occurrences to the federal registry of adverse drug reactions. Allergy skin testing or immunotherapy is inadvisable in patients who take a beta-blocker orally or in the form of ophthalmic eyedrops. The list of relative contraindications to beta-blocker use should be extended to include susceptibility to recurrent anaphylaxis, whether it is idiopathic or due to an identifiable cause.

Full text

PDF
929

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Assem E. S. Adrenergic mechanisms and immediate-type allergy. Clin Allergy. 1974 Jun;4(2):185–194. doi: 10.1111/j.1365-2222.1974.tb01375.x. [DOI] [PubMed] [Google Scholar]
  2. Awai L. E., Mekori Y. A. Insect sting anaphylaxis and beta-adrenergic blockade: a relative contraindication. Ann Allergy. 1984 Jul;53(1):48–49. [PubMed] [Google Scholar]
  3. Barrett-Bee K., Lees J. The nature of the beta-adrenoceptor involved in the inhibition of antigen-induced histamine release. Biochem Biophys Res Commun. 1978 Oct 30;84(4):998–1002. doi: 10.1016/0006-291x(78)91682-0. [DOI] [PubMed] [Google Scholar]
  4. Berkelman R. L., Finton R. J., Elsea W. R. Beta-adrenergic antagonists and fatal anaphylactic reactions to oral penicillin. Ann Intern Med. 1986 Jan;104(1):134–134. doi: 10.7326/0003-4819-104-1-134_1. [DOI] [PubMed] [Google Scholar]
  5. Bickell W. H., Dice W. H. Military antishock trousers in a patient with adrenergic-resistant anaphylaxis. Ann Emerg Med. 1984 Mar;13(3):189–190. doi: 10.1016/s0196-0644(84)80611-3. [DOI] [PubMed] [Google Scholar]
  6. Busse W. W. Decreased granulocyte response to isoproterenol in asthma during upper respiratory infections. Am Rev Respir Dis. 1977 May;115(5):783–791. doi: 10.1164/arrd.1977.115.5.783. [DOI] [PubMed] [Google Scholar]
  7. Butchers P. R., Skidmore I. F., Vardey C. J., Wheeldon A. Characterization of the receptor mediating the antianaphylactic effects of beta-adrenoceptor agonists in human lung tissue in vitro. Br J Pharmacol. 1980;71(2):663–667. doi: 10.1111/j.1476-5381.1980.tb10987.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cass E., Kadar D., Stein H. A. Hazards of phenylephrine topical medication in persons taking propranolol. Can Med Assoc J. 1979 May 19;120(10):1261–1262. [PMC free article] [PubMed] [Google Scholar]
  9. Cleaveland C. R., Rangno R. E., Shand D. G. A standardized isoproterenol sensitivity test. The effects of sinus arrhythmia, atropine, and propranolol. Arch Intern Med. 1972 Jul;130(1):47–52. doi: 10.1001/archinte.130.1.47. [DOI] [PubMed] [Google Scholar]
  10. Dunn T. L., Gerber M. J., Shen A. S., Fernandez E., Iseman M. D., Cherniack R. M. The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. Am Rev Respir Dis. 1986 Feb;133(2):264–268. doi: 10.1164/arrd.1986.133.2.264. [DOI] [PubMed] [Google Scholar]
  11. Feely J., Wilkinson G. R., Wood A. J. Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med. 1981 Mar 19;304(12):692–695. doi: 10.1056/NEJM198103193041202. [DOI] [PubMed] [Google Scholar]
  12. Hamilton G. Severe adverse reactions to urography in patients taking beta-adrenergic blocking agents. Can Med Assoc J. 1985 Jul 15;133(2):122–122. [PMC free article] [PubMed] [Google Scholar]
  13. Hannaway P. J., Hopper G. D. Severe anaphylaxis and drug-induced beta-blockade. N Engl J Med. 1983 Jun 23;308(25):1536–1536. [PubMed] [Google Scholar]
  14. Hiatt W. R., Wolfel E. E., Stoll S., Nies A. S., Zerbe G. O., Brammell H. L., Horwitz L. D. beta-2 Adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol. Clin Pharmacol Ther. 1985 Jan;37(1):2–6. doi: 10.1038/clpt.1985.2. [DOI] [PubMed] [Google Scholar]
  15. Hovmark A., Asbrink E. Effects of a beta-receptor blocking agent (propranolol) on synthesis of IgE in vitro by peripheral blood lymphocytes from atopic patients. Allergy. 1981 Aug;36(6):391–396. doi: 10.1111/j.1398-9995.1981.tb01844.x. [DOI] [PubMed] [Google Scholar]
  16. Ingall M., Goldman G., Page L. B. Beta-blockade in stinging insect anaphylaxis. JAMA. 1984 Mar 16;251(11):1432–1432. [PubMed] [Google Scholar]
  17. Jacobs R. L., Rake G. W., Jr, Fournier D. C., Chilton R. J., Culver W. G., Beckmann C. H. Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade. J Allergy Clin Immunol. 1981 Aug;68(2):125–127. doi: 10.1016/0091-6749(81)90170-6. [DOI] [PubMed] [Google Scholar]
  18. Jones B. Treatment of beta-blocker poisoning. Lancet. 1980 May 10;1(8176):1031–1031. [PubMed] [Google Scholar]
  19. Kaliner M., Shelhamer J. H., Davis P. B., Smith L. J., Venter J. C. Autonomic nervous system abnormalities and allergy. Ann Intern Med. 1982 Mar;96(3):349–357. doi: 10.7326/0003-4819-96-3-349. [DOI] [PubMed] [Google Scholar]
  20. Leier C. V., Baker N. D., Weber P. A. Cardiovascular effects of ophthalmic timolol. Ann Intern Med. 1986 Feb;104(2):197–199. doi: 10.7326/0003-4819-104-2-197. [DOI] [PubMed] [Google Scholar]
  21. Lennard M. S., Tucker G. T., Woods H. F. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1986 Jan-Feb;11(1):1–17. doi: 10.2165/00003088-198611010-00001. [DOI] [PubMed] [Google Scholar]
  22. Lewis R. V., Lennard M. S., Jackson P. R., Tucker G. T., Ramsay L. E., Woods H. F. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1985 Mar;19(3):329–333. doi: 10.1111/j.1365-2125.1985.tb02651.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Madowitz J. S., Schweiger M. J. Severe anaphylactoid reaction to radiographic contrast media. Recurrences despites premedication with diphenhydramine and prednisone. JAMA. 1979 Jun 29;241(26):2813–2815. [PubMed] [Google Scholar]
  24. Matsumura Y., Tan E. M., Vaughan J. H. Histamine hypersensitivity in mice induced by Bordetella pertussis or pharmacologic beta adrenergic blockade. Effects of adrenergic, cholinergic, and other drugs. J Allergy Clin Immunol. 1976 Sep;58(3):395–404. doi: 10.1016/0091-6749(76)90120-2. [DOI] [PubMed] [Google Scholar]
  25. Matsumura Y., Tan E. M., Vaughan J. H. Hypersensitivity to histamine and systemic anaphylaxis in mice with pharmacologic beta adrenergic blockade: protection by nucleotides. J Allergy Clin Immunol. 1976 Sep;58(3):387–394. doi: 10.1016/0091-6749(76)90119-6. [DOI] [PubMed] [Google Scholar]
  26. McLaren E. H. Severe hypertension produced by interaction of phenylpropanolamine with methyldopa and oxprenolol. Br Med J. 1976 Jul 31;2(6030):283–284. doi: 10.1136/bmj.2.6030.283-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Meurs H., Koëter G. H., de Vries K., Kauffman H. F. The beta-adrenergic system and allergic bronchial asthma: changes in lymphocyte beta-adrenergic receptor number and adenylate cyclase activity after an allergen-induced asthmatic attack. J Allergy Clin Immunol. 1982 Oct;70(4):272–280. doi: 10.1016/0091-6749(82)90063-x. [DOI] [PubMed] [Google Scholar]
  28. Miller R. R., Olson H. G., Amsterdam E. A., Mason D. T. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med. 1975 Aug 28;293(9):416–418. doi: 10.1056/NEJM197508282930902. [DOI] [PubMed] [Google Scholar]
  29. Mjörndal T. O., Chesrown S. E., Frey M. J., Reed B. R., Lazarus S. C., Gold W. M. Effect of beta-adrenergic stimulation on experimental canine anaphylaxis in vivo. J Allergy Clin Immunol. 1983 Jan;71(1 Pt 1):62–70. doi: 10.1016/0091-6749(83)90548-1. [DOI] [PubMed] [Google Scholar]
  30. Myers M. G., Wisenberg G. Sudden withdrawal of propranolol in patients with angina pectoris. Chest. 1977 Jan;71(1):24–26. doi: 10.1378/chest.71.1.24. [DOI] [PubMed] [Google Scholar]
  31. Nelson B. L., Dupont L. A., Reid M. J. Prospective survey of local and systemic reactions to immunotherapy with pollen extracts. Ann Allergy. 1986 Apr;56(4):331–334. [PubMed] [Google Scholar]
  32. Newman B. R., Schultz L. K. Epinephrine-resistant anaphylaxis in a patient taking propranolol hydrochloride. Ann Allergy. 1981 Jul;47(1):35–37. [PubMed] [Google Scholar]
  33. Nisam M. R., Zbinden A., Chesrown S., Barnett D., Gold W. M. Distribution oand pharmacological release of histamine in canine lung in vivo. J Appl Physiol Respir Environ Exerc Physiol. 1978 Mar;44(3):455–463. doi: 10.1152/jappl.1978.44.3.455. [DOI] [PubMed] [Google Scholar]
  34. Parmley W. W. The role of glucagon in cardiac therapy. N Engl J Med. 1971 Sep 30;285(14):801–802. doi: 10.1056/NEJM197109302851414. [DOI] [PubMed] [Google Scholar]
  35. Riddell J. G., Shanks R. G. Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses. Clin Pharmacol Ther. 1985 Nov;38(5):554–559. doi: 10.1038/clpt.1985.223. [DOI] [PubMed] [Google Scholar]
  36. Shereff R. H., Harwell W., Lieberman P., Rosenberg E. W., Robinson H. Effect of beta adrenergic stimulation and blockade on immediate hypersensitivity skin test reactions. J Allergy Clin Immunol. 1973 Dec;52(6):328–333. doi: 10.1016/0091-6749(73)90091-2. [DOI] [PubMed] [Google Scholar]
  37. Stark B. J., Sullivan T. J. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol. 1986 Jul;78(1 Pt 1):76–83. doi: 10.1016/0091-6749(86)90117-x. [DOI] [PubMed] [Google Scholar]
  38. Wallin J. D. Beta-adrenergic blockers in the hypertensive asthmatic patient? Chest. 1985 Dec;88(6):801–802. doi: 10.1378/chest.88.6.801. [DOI] [PubMed] [Google Scholar]
  39. Ward D. E., Jones B. Glucagon and beta-blocker toxicity. Br Med J. 1976 Jul 17;2(6028):151–151. doi: 10.1136/bmj.2.6028.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wasserman S. I. The heart in anaphylaxis. J Allergy Clin Immunol. 1986 May;77(5):663–666. doi: 10.1016/0091-6749(86)90405-7. [DOI] [PubMed] [Google Scholar]
  41. Wilcox P. G., Ahmad D., Darke A. C., Parsons J., Carruthers S. G. Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma. Clin Pharmacol Ther. 1986 Jan;39(1):29–34. doi: 10.1038/clpt.1986.5. [DOI] [PubMed] [Google Scholar]
  42. Zaloga G. P., DeLacey W., Holmboe E., Chernow B. Glucagon reversal of hypotension in a case of anaphylactoid shock. Ann Intern Med. 1986 Jul;105(1):65–66. doi: 10.7326/0003-4819-105-1-65. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES